IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials

被引：60
作者：
Leonidas Leiva, Carlos [1 ,2 ]
Gallardo, M. Julian [1 ,2 ]
Casanova, Natalia [1 ,2 ]
Terzolo, Horacio [3 ]
Chacana, Pablo [1 ,2 ]
机构：
[1] Inst Nacl Tecnol Agr, Inst Patobiol, Nicolas Repetto & Los Reseros S-N, Hurlingham, Buenos Aires, Argentina
[2] UEDD INTA CONICET, Inst Patobiol Vet, Nicolas Repetto & Los Reseros S-N, Hurlingham, Buenos Aires, Argentina
[3] Inst Nacl Tecnol Agr, Estn Expt Agr Balcarce, RN 226 Km 73-3, Balcarce, Buenos Aires, Argentina
来源：
INTERNATIONAL IMMUNOPHARMACOLOGY | 2020年 / 81卷
关键词：
Antibodies; Egg yolk; IgY-technology; Therapy; Patent; Clinical trial; PSEUDOMONAS-AERUGINOSA INFECTIONS; HELICOBACTER-PYLORI INFECTION; IMMUNOGLOBULIN IGY; IN-VITRO; ROTAVIRUS; PREVENTION; INHIBITION; COMPLEMENT; PROTECTION; DIARRHEA;
D O I：
10.1016/j.intimp.2020.106269
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Advantages of IgY over other antibodies comprise its cost-effective extraction, the minimization of animal harm and distress, and its reduced reactivity with mammalian factors. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. This review provides a comprehensive analysis of IgY-based biologicals for human medicine, including patent applications and clinical trials during the period 2010-2018, and addresses how IgY-technology can lead to innovation in the production of biologicals for the treatment and prophylaxis of a wide range of infectious and non-communicable diseases.
引用
收藏
页数：10
相关论文
共 110 条
[1]   IgY antibodies for the immunoprophylaxis and therapy of respiratory infections [J].
Abbas, Aymn Talat ;
El-Kafrawy, Sherif Aly ;
Sohrab, Sayed Sartaj ;
Azhar, Esam Ibraheem Ahmed .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (01) :264-275
[2]  
Aiguo B., 2014, China patent, Patent No. [CN104117062, 104117062]
[3]   Recent advances in the pharmacological management of hypercholesterolaemia [J].
Ajufo, Ezim ;
Rader, Daniel J. .
LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05) :436-446
[4]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[5]   IgY against enterotoxigenic Escherichia coli administered by hydrogel-carbon nanotubes composites to prevent neonatal diarrhoea in experimentally challenged piglets [J].
Alustiza, Fabrisio ;
Bellingeri, Romina ;
Picco, Natalia ;
Motta, Carlos ;
Grosso, Maria C. ;
Barbero, Cesar A. ;
Acevedo, Diego F. ;
Vivas, Adriana .
VACCINE, 2016, 34 (28) :3291-3297
[6]  
Amirijavid1 Shaghayegh, 2016, Asian Pac J Cancer Prev, V17, P293
[7]   EFFECT OF TOPICAL ANTI-STREPTOCOCCUS MUTANS IgY GEL ON QUANTITY OF S. MUTANS ON RATS' TOOTH SURFACE [J].
Bachtiar, Endang W. ;
Afdhal, Anggraeni ;
Meidyawati, Ratna ;
Soejoedono, Retno D. ;
Poerwaningsih, Erni .
ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2016, 63 (02) :159-169
[8]   Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice [J].
Bae, Jin-Sik ;
Park, Jong-Min ;
Lee, Junghoon ;
Oh, Byung-Chul ;
Jang, Sang-Ho ;
Lee, Yun Bin ;
Han, Young-Min ;
Ock, Chan-Young ;
Cha, Ji-Young ;
Hahm, Ki-Baik .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 66 :32-44
[9]   Immune System and Chronic Diseases [J].
Bagatini, Margarete Dulce ;
Cardoso, Andreia Machado ;
dos Santos, Alessandra Antunes ;
Carvalho, Fabiano Barbosa .
JOURNAL OF IMMUNOLOGY RESEARCH, 2017, 2017
[10]  
Balls M, 2010, ALTEX-ALTERN ANIM EX, V27, P144
12345678910